An attempt is made to study skin anti‐inflammatory activity for different formulations of Co‐Q10 loaded nanostructured lipid carriers (NLC) including NLC, NLC‐based gel, and W/O cream. NLCs are prepared by a hot high speed homogenization method using cetylpalmitate as solid lipid, coconut oil as liquid lipid, and tween 80 as surfactant. NLCs are characterized by different techniques including dynamic light scattering, transmission electron microscopy, and FT‐IR. Stable formulation with a mean size range of 118.7 ± 6.9 nm and zeta potential of −29.1 ± 1.96 mV is developed. Drug loading content for NLC/Co‐Q10, NLC‐based gel, and W/O cream formulations is 7.945 ± 0.035%, 4.79 ± 0.052%, and 2.39 ±0.041%, respectively. All formulations show high entrapment efficiency (EE) (>96% w/w). The formulations are prepared and characterized in terms of rheology, pH, anti‐radical activity, ex vivo skin permeation, and in vivo anti‐inflammatory activity. A drug release study exhibits that the maximum attainable drug release after 48 h for NLC/Co‐Q10 is 11.94% versus 14.4% for NLC‐based gel and 41.56% for W/O cream. Ex vivo studies on rat skin reveals that Co‐Q10 contained in the W/O cream formulation penetrates into the stratum corneum more readily than that in the NLC/Co‐Q10 and NLC‐based gel formulations. In vivo studies of acute anti‐inflammatory activity of NLC‐based formulations show significant difference between inhibition effect of W/O cream and NLC/Co‐Q10 compared to betamethasone.
Practical Applications: The findings indicate that formulation based on NLC/Co‐Q10 is suitable not only in skin penetration but also in dermatology.
Anti‐inflammatory activity for different formulations of Co‐Q10 loaded NLC including NLC, NLC‐based gel, and W/O cream is investigated. All formulations show suitable physicochemical properties and high drug loading capacity for being used as dermatological formulations. The order of drug release after 48 h is NLC/Co‐Q10 < NLC‐based gel < W/O cream. In ex vivo study, the fastest penetration rate into the stratum corneum is obtained for W/O cream. W/O cream and NLC/Co‐Q10 formulations show significant acute anti‐inflammatory activity compared to betamethasone in in vivo study.